CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
RO7017773 Phase I Capsule +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03847987
NCT03847987Phase 1Completed

A 2 Part, Randomized, Open-Label, Single Dose, Crossover Study to Assess the Relative Bioavailability of Phase II Tablet Formulation Compared to the Current Phase I Capsule Formulation and the Effect of Food and Taste Assessment on the Phase II Tablet Formulation in Healthy Participants

Hoffmann-La Roche·interventional·Posted Feb 20, 2019·Updated May 28, 2020

In Brief

A Phase 1 clinical trial evaluating RO7017773 Phase I Capsule, RO7017773 Phase II Tablet Unflavored, and 1 other intervention for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This is a two-part, open-label, healthy volunteer study. Part I will investigate the relative bioavailability of capsule and tablet formulations of RO7017773. Part II will explore how the taste of the tablet formulation is perceived with and without added sweetener/flavoring.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedFeb 20, 2019
Enrollment StartMar 12, 2019
Primary CompletionApr 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.4 years ago

Interventions

RO7017773 Phase I Capsuledrug

Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.

RO7017773 Phase II Tablet Unflavoreddrug

Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.

RO7017773 Phase II Tablet Sweetened/Flavoreddrug

Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.